Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Calverley, L. Fabbri, F. Martinez, U. M. Goehring, M. Brose, K. Rabe (Liverpool, United Kingdom; Modena, Italy; Ann Arbor, United States Of America; Zurich, Switzerland; Kiel, Germany). Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 3034

Member's Comments

No comment yet.

Related content which might interest you: Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 The relation of comorbidities with the exacerbation severity in patients with COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation Source: Annual Congress 2013 –COPD treatment and others Year: 2013 COPD: Influence of patients’ nutritive status on the exacerbations rate Source: International Congress 2016 – COPD diagnosis and management Year: 2016 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Gender differences in hospitalized patients with acute exacerbation of COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Vitamin D, exacerbations and hospitalizations in COPD patients Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Characterization of readmissions in patients hospitalized with COPD exacerbation Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Factors associated with cognitive dysfunction in COPD patients hospitalised with exacerbations Source: International Congress 2014 – COPD markers Year: 2014 Risk factors for another hospitalization in COPD patients hospitalized for exacerbation Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015